Windsor Regional Hospital to use anti-viral and antibody treatments for high-risk COVID-19 patients - Action News
Home WebMail Saturday, November 23, 2024, 09:08 PM | Calgary | -12.2°C | Regions Advertise Login | Our platform is in maintenance mode. Some URLs may not be available. |
Windsor

Windsor Regional Hospital to use anti-viral and antibody treatments for high-risk COVID-19 patients

Windsor Regional Hospital has been given approval to use two medications one an anti-viral and the other an antibody to treat COVID-19 in positive patients who meet certain criteria.

Both medications in limited supply, only for patients that meet certain criteria

Windsor regional Hospital Ouellette campus is shown in this file photo. The hospital has been approved to use an anti-viral and antibody medication on COVID-19 patients meeting a certain criteria. (Mike Evans/CBC)

Windsor Regional Hospital has been given approval to use two medications one an anti-viral and the other an antibody to treat COVID-19 inpatients who meet certain criteria.

However, both medications are in limited supply, the hospital said in a media statement Friday.

The anti-viral treatment isPfizer'sPaxlovid, which was approved by Health Canada for those18 and olderearlier this month.Paxlovidis an oral antiviral treatment prescribed by a doctor and administered in pill form. It is designed to help the body fight off the SARS-CoV-2 virus, reduce symptoms from an infection and shorten the period of illness.

After months of clinical trials, Pfizer reported in November that Paxlovid reduced the risk of hospitalization or death by a89 per cent compared to a placebo in non-hospitalized high-risk adults with COVID-19.

The drug is supposed to be administered within five days of the onset of COVID-19 symptoms to be effective, with patients taking three pills twice daily for five days.

Windsor Regional Hospital said this drug would be used for high-risk patients who have mild or moderate COVID-19 symptoms.

The other medication,Sotrovimab, is an antibody infusiontreatment which will be prescribed to patientswith mild to moderate COVID-19 symptoms. It wasapproved by Health Canadain July 2021. This treatment is given via IV.

Sotrovimabis recommended as an outpatient treatment to prevent hospitalizationsin "very select populations," according to Windsor Regional Hospital.

The hospital said only certain people will qualify for either treatment, as outlined by Ontario'sCOVID-19 Science Advisory Table. This incudes individuals at ahigher risk of severe illness including:

  • Immunocompromised individualsaged 18 and olderregardless of vaccine status.
  • Unvaccinated individuals aged 60 and over.
  • Unvaccinated First Nation, Inuit and Mtis individuals aged 50 and over.
  • Unvaccinated individuals aged 50 and over with one or more risk factors.

The medications are not replacements for a vaccine, the hospital urged.

Windsor Regional Hospital said that if individuals think they may qualify for the treatments, they should book an appointment at the hospital's Ouellette Campus Clinical Assessment Centre.

Individuals should bring a list of and medical conditions they have, or any medications they are taking.

With files from John Paul Tasker

Add some good to your morning and evening.

Your daily guide to the coronavirus outbreak. Get the latest news, tips on prevention and your coronavirus questions answered every evening.

...

The next issue of the Coronavirus Brief will soon be in your inbox.

Discover all CBC newsletters in theSubscription Centre.opens new window

This site is protected by reCAPTCHA and the Google Privacy Policy and Google Terms of Service apply.